Consolidated loss widens 148% YoY to ₹127.6 Cr as R&D spend surges on Phase 3 trials

Consolidated net loss for the quarter ended 30 June 2026 (Q1 FY27) widened to ₹127.61 Cr, up 147.7% YoY from ₹51.52 Cr and 179.9% QoQ from ₹45.60 Cr, per un-audited results approved by the Board on 6 August 2026. Diluted EPS was -₹4.84 versus -₹2.36 a year ago. Revenue from operations was ₹3.57 Cr against ₹1.87 Cr YoY — traditional margin metrics (NPM/OPM) aren't meaningful here since Suven remains a pre-revenue, clinical-stage biopharmaceutical rather than a commercial-revenue business. Consolidated R&D and operating expenses rose to ₹123.83 Cr from ₹41.49 Cr YoY (+198%) and ₹42.33 Cr QoQ (+193%), the direct driver of the wider loss; standalone R&D was a comparatively modest ₹12.76 Cr, confirming nearly all of the increase sits in the wholly-owned US subsidiary, Suven Neurosciences Inc. The auditor's limited-review report separately discloses the subsidiary posted a ₹111.49 Cr net loss (total comprehensive loss ₹111.47 Cr) on nil revenue for the quarter — consistent with the roughly ₹111.5 Cr gap between standalone (-₹16.12 Cr) and consolidated (-₹127.61 Cr) loss. There was no tax and no exceptional item in either the current or comparison periods, so no adjusted-vs-reported split is needed here. Other income was ₹7.52 Cr, 68% of the ₹11.09 Cr total income, likely interest earned on the ₹857.64 Cr raised via convertible warrants, of which ₹448.14 Cr remained un-utilised as of 30 June 2026 (note 6). No management guidance or prior concall commentary is on record, and a web search turned up no brokerage previews or consensus estimates for this quarter — Suven carries no visible analyst coverage tracking its quarterly P&L, consistent with its status as a pre-commercial, trial-stage name; vs-street and vs-guidance are both unknown. Management's own news release does not address the loss at all, framing the quarter entirely around pipeline milestones instead. The spend is tied to three active programs: SUVN-502 (Masupirdine) for Alzheimer's-related agitation hit 95% enrolment in its global Phase 3 trial, with enrolment completion targeted for September 2026 and a potential database lock/results readout in Q2 CY2027; SUVN-G3031 (Samelisant) started a Phase 3 trial for narcolepsy-related excessive daytime sleepiness in April 2026; and SUVN-911 (Ropanicant) completed Phase 2b in major depressive disorder. With ₹448.14 Cr of warrant proceeds still unutilised, near-term loss and cash-burn trends will likely keep tracking the pace of these trials rather than any commercial revenue ramp.